NURS 6630 Week 6 anxiety treatment plan example

Worry at the Wheel: A Treatment Plan for Generalized Anxiety in a 28-Year-Old Delivery Driver, With Four Mechanisms Compared on Onset, Sedation and Dependence

Student Name

College of Nursing, Walden University

NURS 6630: Neurobiology and Psychopharmacology for Psychiatric Mental Health Advanced Practice Nursing

Instructor Name

Month Day, Year

Worry at the Wheel: A Treatment Plan for Generalized Anxiety in a 28-Year-Old Delivery Driver, With Four Mechanisms Compared on Onset, Sedation and Dependence

Presentation

An invented twenty-eight-year-old delivery driver describes eight months of worry he cannot control about money, his mother's health and making mistakes on his route, with muscle tension in his neck and shoulders, restlessness and difficulty falling asleep. He drives a van for ten hours a day and must stay alert. He drinks rarely and uses no other substances. He scores 15 on the GAD-7, which places him in the severe band, and the case records it as the baseline measure (Spitzer et al., 2006). There is no history of depression, and he has not taken psychiatric medication before. He asks for something to help him sleep and to stop the worry. The plan compares options by mechanism and does not specify doses.

Four Mechanisms Compared

Table 1

Options by Mechanism, Onset, Sedation and Dependence

Reading the Table for This Patient

The benzodiazepine class acts fastest because it enhances the GABA-A chloride channel directly, the same fast receptor family that makes any GABA-A effect immediate (Stahl, 2021). For this patient, that speed comes with two costs that matter more than usual. The first is impaired alertness and reaction time, which is a direct safety issue for a man who drives all day. The second is dependence: in 2020 the Food and Drug Administration required its boxed warning for the whole benzodiazepine class to be updated so that it spells out the dangers of misuse and addiction as well as physical dependence and withdrawal (U.S. Food and Drug Administration [FDA], 2020). The sedating antihistamine shares the first cost without the second, since its sedation may persist into the morning. The 5-HT1A partial agonist avoids both but acts slowly and has a narrower evidence base for severe symptoms.

The plan chooses a selective serotonin reuptake inhibitor for maintenance treatment. Its effect on worry and tension develops over weeks, its sedation is usually low, and it carries no misuse risk (Stahl, 2021). He is told in advance that benefit will build gradually, that nausea or restlessness in the first days usually settles, and that the medication should not be stopped abruptly.

Psychotherapy and Sleep

Cognitive behavioral therapy for generalized anxiety is part of the plan from the start, not an afterthought. It addresses the worry process directly, it is effective on its own and it gives him skills that continue after medication is stopped. A referral is made at the first visit, with the option of evening or telehealth sessions to fit his schedule. For sleep, the plan uses sleep hygiene and a brief behavioral approach in the first weeks rather than a sedating medication, because morning drowsiness is the effect most dangerous to him.

Does the Plan Rule Out Benzodiazepines?

Not permanently. The plan states the circumstances under which short-term use might be reconsidered, such as a severe crisis while off work, and names the conditions: a defined short period, no driving while taking it and a clear stop date agreed in advance. For his daily life as it is, the plan does not use them.

Monitoring

GAD-7 at each visit, with a meaningful fall expected over six to eight weeks. At each visit, questions about daytime alertness, any near misses while driving, sleep and side effects. A check at four weeks on whether he has started psychotherapy. If there is little improvement after an adequate trial, the next step is reviewed with him, and the plan records that the GAD-7 baseline makes that decision measurable rather than a matter of impression.

References

Spitzer, R. L., Kroenke, K., Williams, J. B. W., & Löwe, B. (2006). A brief measure for assessing generalized anxiety disorder: The GAD-7. Archives of Internal Medicine, 166(10), 1092-1097. https://doi.org/10.1001/archinte.166.10.1092

Stahl, S. M. (2021). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (5th ed.). Cambridge University Press.

U.S. Food and Drug Administration. (2020). FDA requiring boxed warning updated to improve safe use of benzodiazepine drug class [Drug safety communication].